Michele Gunsior

Michele Gunsior

Auto-generated profile, based on publicly available information

Michele Gunsior

Viela Bio, Gaithersburg, MD 20878, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JKJodi L. Karnell
Jodi L. Karnell
YWYanping Wu
Yanping Wu
NMNanette Mittereder
Nanette Mittereder
MSMichael A. Smith
Michael A. Smith
MGMichele Gunsior
Michele Gunsior
ATAntonio Terrelonge
Antonio Terrelonge
VIB7734 depletes plasmacytoid dendritic cells and demonstrates clinical benefit in patients with cutaneous lupus.

24 April 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JKJodi L. Karnell
Jodi L. Karnell
MAMarius Albulescu
Marius Albulescu
SDStacey Drabic
Stacey Drabic
LWLiangwei Wang
Liangwei Wang
RMRachel Moate
Rachel Moate
JDJörn Drappa
Jörn Drappa
The CD40/CD40L axis plays a central role in the generation of humoral immune responses and is an attractive target for treating autoimmune diseases in the clinic. Here, we report the generation and clinical results of a CD40L binding protein, VIB4920, which lacks an Fc domain, therefore avoiding platelet-related safety issues observed with earlier monoclonal antibody therapeutics that targeted CD40L. VIB4920 blocked downstream CD40 signaling events, resulting in inhibition of human B cell activation and plasma cell differentiation, and did not induce platelet aggregation in preclinical studies. In a phase 1 study in healthy volunteers, VIB4920 suppressed antigen-specific IgG in a dose-dependent fashion after priming and boosting with the T-dependent antigen, KLH. Furthermore, VIB4920 significantly reduced circulating Ki67+ dividing B cells, class-switched memory B cells, and a plasma cell gene signature after immunization. In a phase 1b proof-of-concept study in patients with rheumatoid arthritis, VIB4920 significantly decreased disease activity, achieving low disease activity or clinical remission in more than 50% of patients in the two higher-dose groups. Dose-dependent decreases in rheumatoid factor autoantibodies and Vectra DA biomarker score provide additional evidence that VIB4920 effectively blocked the CD40/CD40L pathway. VIB4920 demonstrated a good overall safety profile in both clinical studies. Together, these data demonstrate the potential of VIB4920 to significantly affect autoimmune disease and humoral immune activation and to support further evaluation of this molecule in inflammatory conditions.

30 September 2025 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
YNYan G. Ni
Yan G. Ni
LSLauren F. Stevenson
Lauren F. Stevenson
LALakshmi Amaravadi
Lakshmi Amaravadi
CFCarmen Fernández-Metzler
Carmen Fernández-Metzler
LKLindsay King
Lindsay King
KQKaren J. Quadrini
Karen J. Quadrini

13 January 2026 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
LKLindsay King
Lindsay King
JAJohn Allinson
John Allinson
LALakshmi Amaravadi
Lakshmi Amaravadi
RKRobert Kernstock
Robert Kernstock
FGFabio Garofolo
Fabio Garofolo
TVTroy Voelker
Troy Voelker